LabConnect Launches its Global Sample Tracking Solution
LabConnect
has released its proprietary clinical trial sample tracking and management service, SampleGISTICS™.
Today’s clinical trials have increasingly complex analytical requirements that necessitate the utilization of multiple testing and biostorage facilities worldwide. This has led to gaps in sample visibility and downstream data management issues. “LabConnect developed this sample tracking service because of our clients’ need to locate their samples and data to effectively manage complex global clinical trials,” said Eric Hayashi, President and Chief Executive Officer. “Central laboratories have filled logistical and distribution gaps, but did not historically track the life cycle of samples, resulting in millions of dollars in unnecessary expenses, such as, lost samples, payroll costs, and time. LabConnect has the solution.”
The backbone of SampleGISTICS™ is LabConnect’s proprietary software, SampleREACH™, which provides Web-based, real-time sample tracking including collection, shipment, and receipt at any laboratory or location worldwide. In addition, the software enables instant accessioning, resulting in immediate identification and correction of queries including sample collection issues. SampleREACH™ provides detailed information about clients' samples including location, temperature, volume, freeze/thaw cycles, clinical data and has the ability to extract customizable reports. The tool’s forecast module makes budgeting more efficient and identifies when samples are missing.
As part of LabConnect’s complete laboratory services spanning a worldwide network of laboratories, SampleGISTICS™ eliminates the need to manually track samples by consolidating all of the information to one location. SampleGISTICS™ aims to significantly decreases the workload of site and clinical operations staff, allowing for faster decision making and a cost effective outcome.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025